J
Josep Comin Colet
Researcher at Autonomous University of Barcelona
Publications - 13
Citations - 2165
Josep Comin Colet is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 7, co-authored 8 publications receiving 1839 citations.
Papers
More filters
Journal ArticleDOI
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency.
Stefan D. Anker,Josep Comin Colet,Gerasimos Filippatos,Ronnie Willenheimer,Kenneth Dickstein,Helmut Drexler,Thomas F. Lüscher,Boris Bart,Waldemar Banasiak,Joanna Niegowska,Bridget Anne Kirwan,Claudio Mori,Barbara von Eisenhart Rothe,Stuart J. Pocock,Philip A. Poole-Wilson,Piotr Ponikowski +15 more
TL;DR: Treatment with intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, improves symptoms, functional capacity, and quality of life; the side-effect profile is acceptable.
Journal ArticleDOI
Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial.
Gerasimos Filippatos,Dimitrios Farmakis,Josep Comin Colet,Kenneth Dickstein,Kenneth Dickstein,Thomas F. Lüscher,Ronnie Willenheimer,John Parissis,Giedrius Gaudesius,Claudio Mori,Barbara von Eisenhart Rothe,Nicola Greenlaw,Ian Ford,Piotr Ponikowski,Stefan D. Anker +14 more
TL;DR: Therapy with i.v. iron in patients with chronic heart failure (CHF) and iron deficiency (ID) improves symptoms, functional capacity, and quality of life and whether these beneficial outcomes are independent of anaemia is investigated.
Journal ArticleDOI
The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations
Markku S. Nieminen,Kenneth Dickstein,Cândida Fonseca,José Antonio Magaña Serrano,John Parissis,Francesco Fedele,Gerhard Wikström,Piergiuseppe Agostoni,Shaul Atar,Loant Baholli,Dulce Brito,Josep Comin Colet,István Édes,Juan E. Mesa,Vojka Gorjup,Eduardo Heberto Herrera Garza,Jose Ramon Gonzalez Juanatey,Nenad Karanovic,Apostolos Karavidas,Igor Katsytadze,Matti Kivikko,S T Matskeplishvili,Béla Merkely,Fabrizio Morandi,Angel Novoa,Fabrizio Oliva,Petr Ostadal,Antonio Carlos Pereira-Barretto,Piero Pollesello,Alain Rudiger,Robert H. G. Schwinger,Manfred Wieser,Igor Yavelov,Robert Zymliński +33 more
TL;DR: A panel of 34 experts in the field of cardiology and intensive cardiac care from 21 countries around the world convened for reviewing the existing data on quality of life in patients with advanced heart failure, discussing and reaching a consensus on the validity and significance of quality-of-life assessment methods.
Journal ArticleDOI
Rationale and design of Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure (FAIR‐HF) study: a randomized, placebo‐controlled study of intravenous iron supplementation in patients with and without anaemia
Stefan D. Anker,Josep Comin Colet,Gerasimos Filippatos,Ronnie Willenheimer,Kenneth Dickstein,Kenneth Dickstein,Helmut Drexler,Thomas F. Lüscher,Claudio Mori,Barbara von Eisenhart Rothe,Stuart J. Pocock,Philip A. Poole-Wilson,Piotr Ponikowski +12 more
TL;DR: FAIR‐HF (Clinical Trials.gov NCT00520780) was designed to determine the effect of i.v. iron repletion therapy using ferric carboxymaltose on self‐reported patient global assessment (PGA) and New York Heart Association (NYHA) in patients with CHF and ID.
Journal ArticleDOI
The impact of intravenous ferric carboxymaltose on renal function: An analysis of the FAIR-HF study
Piotr Ponikowski,Gerasimos Filippatos,Josep Comin Colet,Ronnie Willenheimer,Kenneth Dickstein,Kenneth Dickstein,Thomas F. Lüscher,Giedrius Gaudesius,Barbara von Eisenhart Rothe,Claudio Mori,Nicola Greenlaw,Ian Ford,Iain C. Macdougall,Stefan D. Anker +13 more
TL;DR: The FAIR-HF trial as mentioned in this paper randomized 459 CHF patients with iron deficiency (ferritin 0.20 for interactions) and found no interaction between the favorable effects of FCM and baseline renal function.